SGEF is overexpressed in prostate cancer and contributes to prostate cancer progression

Hongtao Wang, Ruiqin Wu, Lan Yu, Feima Wu, Shanhu Li, Yali Zhao, Hailiang Li, Guolan Luo, Jian Wang, Jianguang Zhou

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The purpose of this study was to investigate the potential roles of the SH3-containing guanine nucleotide exchange factor (SGEF) in human prostate cancer. Experimental data showed that SGEF was overexpressed in human prostate cancer cells and specimens. The reduction of SGEF expression through an SGEF-targeting siRNA in androgen-independent C4-2 and C4-2B cells suppressed both anchorage-dependent and anchorage-independent growth. In addition, the androgen receptor (AR) antagonist bicalutamide further strengthened this inhibitory effect due to the suppression of the elevated AR transactivation after knockdown of SGEF. Collectively, our results provide the first demonstration that SGEF is a novel promoter of human prostate cancer progression and development.

Original languageEnglish (US)
Pages (from-to)1468-1474
Number of pages7
JournalOncology reports
Issue number4
StatePublished - Oct 2012
Externally publishedYes


  • AR transactivation
  • Androgen receptor
  • Bicalutamide
  • Prostate cancer
  • SGEF expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'SGEF is overexpressed in prostate cancer and contributes to prostate cancer progression'. Together they form a unique fingerprint.

Cite this